Clinical trials: Ulcer, Gastric
Obesity, Roux-en-y Anastomosis Site
FundoRing Roux-en-Y Gastric Bypass Versus FundoRing One Anastomosis Gastric Bypass
Metabolic and bariatric surgery (MBS) is an effective and durable treatment of severe obesity and its co-morbidities. Gastric bypass is one of the main MBS procedures and is performed using various surgical techniques.
- Conditions
- Obesity, Roux-en-y Anastomosis Site, Reflux Gastritis, Reflux Esophagitis
- Trial name
- FundoRing_RY (NCT07486765)
- Testing
- Laparoscopic FundoRing gastric bypass
- Where
- Kazakhstan
- Volunteers
- 200 people
- Sponsor
- The Society of Bariatric and Metabolic Surgeons of Kazakhstan
Reflux Esophagitis
Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation
The purpose of this study is to exploratorily evaluate the effect of vonoprazan 20 mg on sleep disturbance of patients with reflux esophagitis, who have heartburn and/or regurgitation and ≥ 6.0 in the Pittsburgh Sleep Quality…
- Trial name
- VISTAEXE (NCT03116841)
- Testing
- Vonoprazan
- Where
- 6 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Takeda
Helicobacter Pylori, Gastritis
Safety and Immunogenicity of Chiron's Investigational H. Pylori Vaccine in Healthy Adults
This study was designed to investigate the safety and immunogenicity of Chiron's investigational H. pylori (HP3) vaccine
- Conditions
- Helicobacter Pylori, Gastritis, Gastric Cancer, Gastroduodenal Ulcers
- Trial name
- NCT00613665
- Testing
- helicobacter pylori vaccine
- Where
- Germany
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Peptic Esophagitis, Peptic Ulcer
Diagnostic Value of Fecal Calprotectin in Disorders of the Upper Gastrointestinal Tract
Fecal calprotectin is a very sensitive non-invasive inflammation marker in the detection of inflammatory bowel disease and, to a lesser degree, has also proven to be useful in adenomatous polyps, neoplasias, and infectious…
- Conditions
- Peptic Esophagitis, Peptic Ulcer, Functional Dyspepsia, Irritable Bowel Syndrome
- Trial name
- NCT00920400
- Where
- Switzerland
- Volunteers
- 287 people
- Sponsor
- University Hospital, Basel, Switzerland
Duodenal Ulcer
Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer
This is a multi-center, randomized, double-blind, double-dummy, parallel-group, active-controlled Phase III clinical study to evaluate the efficacy and safety of LXI-15028 50mg comparing with Lansoprazole 30 mg after the…
- Trial name
- NCT05010954
- Testing
- LXI-15028 50mg group, Lansoprazole 30mg group
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Reflux Esophagitis
A Prospective Cohort Study on Endoscopic Features of Upper Gastrointestinal Tract at High Altitude (Zaduo County)
To prospectively enroll participants undergoing gastroscopy at Zaduo County People's Hospital and perform paired analyses with matched cases from Jilin Province.
- Trial name
- NCT07755384
- Testing
- Sedated gastroscopy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jilin University
Peptic Ulcer, Bleeding
Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy
The investigators previously showed that the use of a high-dose intravenous PPI regimen after endoscopic control of bleeding from peptic ulcers reduced rate of recurrent bleeding, decreased the need for endoscopic and surgical…
- Trial name
- IOE (NCT01142245)
- Testing
- Oral esomeprazole, Intravenous Esomeprazole
- Where
- 2 sites in China
- Volunteers
- 263 people
- Sponsor
- Chinese University of Hong Kong
Reflux Esophagitis, Gastric Ulcer
A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer
This is an open label, parallel group, multi-centre, phase III study to assess the safety and efficacy of D961H in maintenance therapy following initial healing therapy in Japanese paediatric patients with reflux esophagitis, and…
- Conditions
- Reflux Esophagitis, Gastric Ulcer, Duodenal Ulcer
- Trial name
- NCT03553563
- Testing
- D961H capsule 10mg, D961H sachet 10mg
- Where
- 15 sites in Japan
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Peptic Ulcer/Erosions
Famotidine Compared With Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion
Low-dose aspirin can prevent cerebral and cardiovascular accidents in individuals with symptomatic atherothrombotic disease, but its use is frequently limited by gastrointestinal side effects.
- Trial name
- NCT00843063
- Testing
- pantoprazole vs famotidine
- Where
- China
- Volunteers
- 161 people
- Sponsor
- Ruttonjee Hospital
Erosive Esophagitis
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
The purpose of this study was to determine the effect of morning versus bedtime administration of omeprazole/sodium bicarbonate (Zegerid) on endoscopic healing for patients with moderate or severe reflux esophagitis.
- Trial name
- NCT00693225
- Testing
- Omeprazole/sodium bicarbonate
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Yvonne Romero
Peptic Ulcer, Bleeding
TAE and Surgery in Patients With Peptic Ulcer Bleeding Uncontrolled by Endoscopic Therapy
The aim of the study is to compare the outcomes of trans-catheter arterial embolization (TAE) and surgery as salvage therapy of peptic ulcer bleeding after failed endoscopic therapy.
- Trial name
- NCT00766961
- Testing
- Trans-catheter arterial embolization, Surgery
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Chinese University of Hong Kong
NSAID Associated Gastric Ulcers
Prevention of Gastric Ulcers
Nonsteroidal anti-inflammatory drugs (NSAIDS) are often associated with gastric ulcers. This study looks at the prevention of these gastric ulcers with one of the three following treatment groups for up to 8 weeks: esomeprazole…
- Trial name
- NCT00629512
- Testing
- Esomeprazole
- Volunteers
- 504 people
- Sponsor
- AstraZeneca
Coronary Artery Disease, Percutaneous Coronary Intervention
Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
The primary aim of this study is to evaluate the efficacy and safety of novel P-CAB (tegoprazan 50 mg once daily) as compared with standard PPI (rabeprazole 20 mg once daily) for protection of GI events in patients with known…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Acute Coronary Syndrome, Myocardial Infarction
- Trial name
- PROTECT-HBR (NCT04416581)
- Testing
- PPI, P-CAB 50
- Where
- 45 sites in South Korea
- Volunteers
- 3,320 people
- Sponsor
- Duk-Woo Park, MD
Peptic Ulcer
Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer
Whether H2 receptor antagonist can prevent thienopyridine-related peptic ulcer remains unclear.
- Trial name
- NCT02418312
- Testing
- histamine-2 receptor antagonist
- Where
- Taiwan
- Volunteers
- 228 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Stress Ulcer
Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit
Pharmacologic stress ulcer prophylaxis is routinely used in the intensive care unit (ICU) to prevent upper gastrointestinal (GI) bleeding in critically ill patients.
- Trial name
- NCT06225167
- Testing
- To evaluate the effectiveness and safety of a pharmacist-driven protocol to discontinue stress ulcer prophylaxis in ICU patients when it is no longer indicated according to pre-defined criteria.
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Methodist Health System
Peptic Ulcer
PPI vs H2RA in Patients With Helicobacter Pylori-Negative Idiopathic Bleeding Ulcers
The aim of this study is to compare the efficacy of a proton pump inhibitor (lansoprazole) and a histamine-2 receptor antagonist (famotidine) in preventing recurrent ulcer bleeding in patients with a history of H.
- Trial name
- NCT01180179
- Testing
- Lansoprazole, Famotidine
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Chinese University of Hong Kong
Chronic Use of Acid Suppressive Medication, GORD
On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication
The purpose of this study is to investigate several aspects of chronic use of acid suppressing medication: dependence on maintenance therapy, the possibilities for on-demand use, and predictors (patient characteristics) for daily…
- Conditions
- Chronic Use of Acid Suppressive Medication, GORD, GERD, Reflux
- Trial name
- NCT00161096
- Testing
- pantoprazole 20 mg (drug)
- Volunteers
- 276 people
- Sponsor
- UMC Utrecht
Peptic Ulcer Hemorrhage
Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage
This is a multicenter, randomized, double-blind, parallel-group, dose-ranging, comparator-controlled study of the effect of pantoprazole on intragastric pH after successful endoscopic hemostasis in hospitalized patients.
- Trial name
- NCT00037570
- Testing
- Pantoprazole
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Gastric Ulcer
Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.
This clinical trial is an open-label, randomized, fasting, single-dose, two-sequence, two-period, crossover study in healthy subjects to evaluate the bioequivalence of "Vonopzan Tablets 20 mg(Vonoprazan Fumarate)" of Hanlim…
- Trial name
- NCT06642987
- Testing
- Vonoprazan Test 20mg, Vonoprazan Reference 20mg
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanlim Pharm. Co., Ltd.
Refractory Reflux Esophagitis
Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)
This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole (D961H) 20 mg once daily in patients (in the form of…
- Trial name
- NCT01669811
- Testing
- Esomeprazole (D961H) twice daily, Esomeprazole (D961H) once daily
- Where
- 63 sites in Japan
- Volunteers
- 1,398 people
- Sponsor
- AstraZeneca